<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>During the period 1971 and 1990, 500 patients underwent resection for <z:mp ids='MP_0002038'>carcinoma</z:mp> of the esophagus, 51 of whom had an associated <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Of these, 49 had <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and two had <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Barrett's <z:mp ids='MP_0002038'>carcinoma</z:mp> accounted for 23.7 percent of the surgically treated <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> during this period </plain></SENT>
<SENT sid="3" pm="."><plain>Reflux symptoms were present in 13 patients preoperatively </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> developed in four patients who had undergone previous antireflux operation and in two patients on the surveillance program </plain></SENT>
<SENT sid="5" pm="."><plain>By postresection staging, 18 patients had stage II <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and 33 patients had stages III and IV <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Stage and length of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> were the only prognostic determinants </plain></SENT>
<SENT sid="7" pm="."><plain>The overall 90 day hospital mortality rate was 17.6 percent </plain></SENT>
<SENT sid="8" pm="."><plain>The hospital mortality rate before 1986 was 22.9 percent, but decreased to 6.3 percent in the last five years </plain></SENT>
<SENT sid="9" pm="."><plain>The one, two and five year survival rates were 45.9, 25.0 and 13.6 percent, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>The five year survival rate was significantly greater for patients with stage II (25 percent) than for patients with stages III and IV (4.5 percent) (p less than 0.05) and for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> length less than 6 centimeters (21 percent) than for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> greater than 6 centimeters (zero percent; p less than 0.001) </plain></SENT>
</text></document>